Taysha CEO steps down after patent fights with patient families, job cuts
Taysha Gene Therapies CEO RA Session II has resigned following a turbulent year in which the company shelved most of its rare disease pipeline and faced criticism from families for blocking plans to restart a drug program.
Session, who will remain a member of the board of directors, will be succeeded by Sean Nolan, the board’s chairman. The changes are effective immediately, Taysha said Friday in a news release. Nolan said his plans call for expediting the company’s lead programs and strengthening a recent partnership with Astellas that brought in $50 million.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.